Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.

By R. Schrier, R. Estacio, A. Esler, P. Mehler. Kidney International, 2002

888 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/c1189e21a6e71ff955a5b673353f9ffd716ae4ca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. S. Laurent
3. M. Woodward
4. F. Turnbull
5. E. Schiffrin
6. H. S. Boudier
7. B. K. Pedersen
8. B. Saltin

In Endocrinology, Diabetes and Metabolism

1. M. Woodward
2. Philippe van de Borne
3. F. Turnbull

Citations in the corpus

• Risk Factors for Renal Dysfunction in Type 2 Diabetes (2006, neutral): “1) Previous retinopathy 543 (19) 681 (20) Previous sensory neuropathy 847 (22) 1094 (22) Previous CVD 761 (19) 974 (19)”
• ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “9).(274,276,329) No effect of antihypertensive therapy on diabetic retinopathy has been reported in normotensive and hypertensive patients in the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial,(508) and in the normotensive type-1 diabetics of”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, result): “For diabetes, the evidence is limited to: (i) the small ‘normotensive’ Appropriate Blood Pressure in Diabetes (ABCD) trial, in which the definition of normotension was unusual (<160mmHg SBP) and benefit of treatment was seen only in one of several secondary CV events [274], and (ii) subgroup analyse”